RESUMEN
Anthrax is caused by Bacillus anthracis and can result in nearly 100% mortality due in part to anthrax toxin. Antimalarial amodiaquine (AQ) acts as a host-oriented inhibitor of anthrax toxin endocytosis. Here, we determined the pharmacokinetics and safety of AQ in mice, rabbits, and humans as well as the efficacy in the fly, mouse, and rabbit models of anthrax infection. In the therapeutic-intervention studies, AQ nearly doubled the survival of mice infected subcutaneously with a B. anthracis dose lethal to 60% of the animals (LD60). In rabbits challenged with 200 LD50 of aerosolized B. anthracis, AQ as a monotherapy delayed death, doubled the survival rate of infected animals that received a suboptimal amount of antibacterial levofloxacin, and reduced bacteremia and toxemia in tissues. Surprisingly, the anthrax efficacy of AQ relies on an additional host macrophage-directed antibacterial mechanism, which was validated in the toxin-independent Drosophila model of Bacillus infection. Lastly, a systematic literature review of the safety and pharmacokinetics of AQ in humans from over 2â¯000 published articles revealed that AQ is likely safe when taken as prescribed, and its pharmacokinetics predicts anthrax efficacy in humans. Our results support the future examination of AQ as adjunctive therapy for the prophylactic anthrax treatment.
Asunto(s)
Carbunco , Bacillus anthracis , Amodiaquina , Animales , Carbunco/tratamiento farmacológico , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Levofloxacino , Ratones , Conejos , Revisiones Sistemáticas como AsuntoRESUMEN
The use of antibiotics is a vital means of treating infections caused by the bacteria Bacillus (B.) anthracis. Importantly, with the potential future use of multidrug-resistant strains of B. anthracis as bioweapons, new antibiotics are needed as alternative therapeutics. In this blinded study, we assessed the protective efficacy of teixobactin, a recently discovered antibiotic, against inhalation anthrax infection in the adult rabbit model. New Zealand White rabbits were infected with a lethal dose of B. anthracis Ames spores via the inhalation route, and blood samples were collected at various times to assess antigenemia, bacteremia, tissue bacterial load, and antibody production. Treatments were administered upon detection of B. anthracis protective antigen in the animals' sera. For comparison, a fully protective dose of levofloxacin was used as a positive control. Rabbits treated with teixobactin showed 100% survival following infection, and the bacteremia was completely resolved by 24-48 h post-treatment. In addition, the bacterial/spore loads in tissues of the animals treated with teixobactin were either zero or dramatically less relative to that of the negative control animals. Moreover, microscopic evaluation of the tissues revealed decreased pathology following treatment with teixobactin. Overall, these results show that teixobactin was protective against inhalation anthrax infection in the rabbit model, and they indicate the potential of teixobactin as a therapeutic for the disease.
RESUMEN
The high case-fatality rates and potential for use as a biological weapon make Nipah virus (NiV) a significant public health concern. Previous studies assessing the pathogenic potential of NiV delivered by the aerosol route in African green monkeys (AGMs) used the Malaysia strain (NiVM), which has caused lower instances of respiratory illness and person-to-person transmission during human outbreaks than the Bangladesh strain (NiVB). Accordingly, we developed a small particle aerosol model of NiVB infection in AGMs. Consistent with other mucosal AGM models of NiVB infection, we achieved uniform lethality and disease pathogenesis reflective of that observed in humans.
Asunto(s)
Infecciones por Henipavirus/virología , Virus Nipah/clasificación , Virus Nipah/fisiología , Aerosoles , Animales , Infecciones por Henipavirus/patologíaRESUMEN
Background: Nipah virus (NiV) is a paramyxovirus (genus Henipavirus) that can cause severe respiratory illness and encephalitis in humans. Transmission occurs through consumption of NiV-contaminated foods, and contact with NiV-infected animals or human body fluids. However, it is unclear whether aerosols derived from aforesaid sources or others also contribute to transmission, and current knowledge on NiV-induced pathogenicity after small-particle aerosol exposure is still limited. Methods: Infectivity, pathogenicity, and real-time dissemination of aerosolized NiV in Syrian hamsters was evaluated using NiV-Malaysia (NiV-M) and/or its recombinant expressing firefly luciferase (rNiV-FlucNP). Results: Both viruses had an equivalent pathogenicity in hamsters, which developed respiratory and neurological symptoms of disease, similar to using intranasal route, with no direct correlations to the dose. We showed that virus replication was predominantly initiated in the lower respiratory tract and, although delayed, also intensely in the oronasal cavity and possibly the brain, with gradual increase of signal in these regions until at least day 5-6 postinfection. Conclusion: Hamsters infected with small-particle aerosolized NiV undergo similar clinical manifestations of the disease as previously described using liquid inoculum, and exhibit histopathological lesions consistent with NiV patient reports. NiV droplets could therefore play a role in transmission by close contact.
Asunto(s)
Aerosoles/administración & dosificación , Infecciones por Henipavirus , Virus Nipah/patogenicidad , Administración por Inhalación , Animales , Cricetinae , Modelos Animales de Enfermedad , Infecciones por Henipavirus/diagnóstico por imagen , Infecciones por Henipavirus/patología , Infecciones por Henipavirus/transmisión , Infecciones por Henipavirus/virología , Luciferasas de Luciérnaga/genética , Luciferasas de Luciérnaga/metabolismo , Pulmón/diagnóstico por imagen , Pulmón/patología , Pulmón/virología , Mesocricetus , Imagen Óptica , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismoRESUMEN
The national blueprint for biodefense concluded that the United States is underprepared for biological threats. The licensed anthrax vaccine absorbed vaccine, BioThrax, requires administration of at least 3-5 intramuscular doses. The anthrax vaccine absorbed vaccine consists of complex cell-free culture filtrates of a toxigenic Bacillus anthracis strain and causes tenderness at the injection site and significant adverse events. We integrated a codon-optimized, protective antigen gene of B. anthracis (plus extracellular secretion machinery), into the chromosome of the licensed, oral, live-attenuated typhoid fever vaccineTy21a to form Ty21a-PA-01 and demonstrated excellent expression of the gene encoding protective antigen. We produced the vaccine in a 10-L fermenter; foam-dried and vialed it, and characterized the dried product. The vaccine retained ~50% viability for 20 months at ambient temperature. Sera from animals immunized by the intraperitoneal route had high levels of anti-protective antigen antibodies by enzyme-linked immunosorbent assay and anthrax lethal toxin-neutralizing activity. Immunized mice were fully protected against intranasal challenge with ~5 LD50 of B. anthracis Sterne spores, and 70% (7/10) of vaccinated rabbits were protected against aerosol challenge with 200 LD50 of B. anthracis Ames spores. There was a significant correlation between protection and antibody levels determined by enzyme-linked immunosorbent assay and toxin-neutralizing activity. These data provide the foundation for achievement of our ultimate goal, which is to develop an oral anthrax vaccine that is stable at ambient temperatures and induces the rapid onset of durable, high-level protection after a 1-week immunization regimen.
RESUMEN
Currently, no plague vaccine exists in the United States for human use. The capsular antigen (Caf1 or F1) and two type 3 secretion system (T3SS) components, the low-calcium-response V antigen (LcrV) and the needle protein YscF, represent protective antigens of Yersinia pestis We used a replication-defective human type 5 adenovirus (Ad5) vector and constructed recombinant monovalent and trivalent vaccines (rAd5-LcrV and rAd5-YFV) that expressed either the codon-optimized lcrV or the fusion gene designated YFV (consisting of ycsF, caf1, and lcrV). Immunization of mice with the trivalent rAd5-YFV vaccine by either the intramuscular (i.m.) or the intranasal (i.n.) route provided protection superior to that with the monovalent rAd5-LcrV vaccine against bubonic and pneumonic plague when animals were challenged with Y. pestis CO92. Preexisting adenoviral immunity did not diminish the protective response, and the protection was always higher when mice were administered one i.n. dose of the trivalent vaccine (priming) followed by a single i.m. booster dose of the purified YFV antigen. Immunization of cynomolgus macaques with the trivalent rAd5-YFV vaccine by the prime-boost strategy provided 100% protection against a stringent aerosol challenge dose of CO92 to animals that had preexisting adenoviral immunity. The vaccinated and challenged macaques had no signs of disease, and the invading pathogen rapidly cleared with no histopathological lesions. This is the first report showing the efficacy of an adenovirus-vectored trivalent vaccine against pneumonic plague in mouse and nonhuman primate (NHP) models.
Asunto(s)
Adenovirus Humanos/genética , Portadores de Fármacos , Vacuna contra la Peste/inmunología , Peste/prevención & control , Administración Intranasal , Animales , Anticuerpos Antibacterianos/sangre , Antígenos Bacterianos/genética , Antígenos Bacterianos/inmunología , Modelos Animales de Enfermedad , Femenino , Esquemas de Inmunización , Inyecciones Intramusculares , Interferón gamma/metabolismo , Macaca fascicularis , Masculino , Ratones , Peste/patología , Vacuna contra la Peste/administración & dosificación , Vacuna contra la Peste/genética , Análisis de Supervivencia , Linfocitos T/inmunología , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunología , Replicación Viral , Yersinia pestis/genética , Yersinia pestis/inmunologíaRESUMEN
Ricin toxin, a type 2 ribosome-inactivating protein and a category B bioterrorism agent, is produced from the seeds of castor oil plant (Ricinus communis). Chronic pathological changes in survivors of aerosolized ricin exposure have not been reported in primates. Here we compare and contrast the pathological changes manifested between rhesus macaques (RM) that succumbed to lethal dose of ricin (group I) and survivor RM exposed to low dose of ricin (group II). All animals in group I exhibited severe diffuse, necrotizing bronchiolitis and alveolitis with fibrinopurulent bronchointerstitial pneumonia, massive alveolar, perivascular and peribronchial/bronchiolar edema with hemorrhage, and necropurulent and hemorrhagic tracheobronchial lymphadenitis. All animals from group II had multifocal, fibrosing interstitial pneumonia with prominent alveolar histiocytosis and type II pneumocyte hyperplasia. Subacute changes like infiltration by lymphocytes and plasma cells and persistence of edematous fluid were occasionally present in lung and tracheobronchial lymph nodes. The changes appear to be a continuum wherein the inflammatory response shifts from an acute to subacute/chronic reparative process if the animals can survive the initial insult.
Asunto(s)
Aerosoles , Pulmón , Ricina , Administración por Inhalación , Aerosoles/administración & dosificación , Animales , Pulmón/efectos de los fármacos , Pulmón/patología , Macaca mulatta , Necrosis/inducido químicamente , Necrosis/patología , Edema Pulmonar/inducido químicamente , Edema Pulmonar/patología , Ricina/administración & dosificación , Ricina/toxicidad , Pruebas de Toxicidad , Pruebas de Toxicidad SubagudaRESUMEN
Eastern equine encephalitis virus (EEEV) is a mosquito-borne alphavirus that causes sporadic, often fatal disease outbreaks in humans and equids, and is also a biological threat agent. Two chimeric vaccine candidates were constructed using a cDNA clone with a Sindbis virus (SINV) backbone and structural protein genes from either a North (SIN/NAEEEV) or South American (SIN/SAEEEV) strain of EEEV. The vaccine candidates were tested in a nonhuman primate (NHP) model of eastern equine encephalitis (EEE). Cynomolgus macaques were either sham-vaccinated, or vaccinated with a single dose of either SIN/NAEEEV or SIN/SAEEEV. After vaccination, animals were challenged by aerosol with a virulent North American strain of EEEV (NA EEEV). The SIN/NAEEEV vaccine provided significant protection, and most vaccinated animals survived EEEV challenge (82%) with little evidence of disease, whereas most SIN/SAEEEV-vaccinated (83%) and control (100%) animals died. Protected animals exhibited minimal changes in temperature and cardiovascular rhythm, whereas unprotected animals showed profound hyperthermia and changes in heart rate postexposure. Acute inflammation and neuronal necrosis were consistent with EEEV-induced encephalitis in unprotected animals, whereas no encephalitis-related histopathologic changes were observed in the SIN/NAEEEV-vaccinated animals. These results demonstrate that the chimeric SIN/NAEEEV vaccine candidate protects against an aerosol EEEV exposure.
Asunto(s)
Virus de la Encefalitis Equina del Este/inmunología , Encefalomielitis Equina/prevención & control , Virus Sindbis/genética , Vacunas Virales/inmunología , Aerosoles , Animales , Modelos Animales de Enfermedad , Portadores de Fármacos , Virus de la Encefalitis Equina del Este/genética , Encefalomielitis Equina/inmunología , Encefalomielitis Equina/mortalidad , Encefalomielitis Equina/patología , Femenino , Fiebre/prevención & control , Vectores Genéticos , Macaca , Masculino , Análisis de Supervivencia , Taquicardia/prevención & control , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunología , Vacunas Virales/administración & dosificación , Vacunas Virales/genéticaRESUMEN
BACKGROUND: Sigma H (sigH) is a major Mycobacterium tuberculosis (Mtb) stress response factor. It is induced in response to heat, oxidative stress, cell wall damage, and hypoxia. Infection of macrophages with the Δ-sigH mutant generates more potent innate immune response than does infection with Mtb. The mutant is attenuated for pathology in mice. METHODS: We used a nonhuman primate (NHP) model of acute tuberculosis, to better understand the phenotype of the Δ-sigH mutant in vivo. NHPs were infected with high doses of Mtb or the mutant, and the progression of tuberculosis was analyzed in both groups using clinical, pathological, microbiological, and immunological parameters. RESULTS: Animals exposed to Mtb rapidly progressed to acute pulmonary tuberculosis as indicated by worsening clinical correlates, high lung bacterial burden, and granulomatous immunopathology. All the animals rapidly succumbed to tuberculosis. On the other hand, the NHPs exposed to the Mtb:Δ-sigH mutant did not exhibit acute tuberculosis, instead showing significantly blunted disease. These NHPs survived the entire duration of the study. CONCLUSIONS: The Mtb:Δ-sigH mutant is completely attenuated for bacterial burden as well as immunopathology in NHPs. SigH and its regulon are required for complete virulence in primates. Further studies are needed to identify the molecular mechanism of this attenuation.
Asunto(s)
Proteínas Bacterianas/metabolismo , Regulación Bacteriana de la Expresión Génica/fisiología , Pulmón/inmunología , Pulmón/microbiología , Mycobacterium tuberculosis/metabolismo , Factor sigma/metabolismo , Tuberculosis Pulmonar/microbiología , Animales , Proteínas Bacterianas/genética , Perfilación de la Expresión Génica , Granuloma , Inmunohistoquímica , Macaca mulatta , Mycobacterium tuberculosis/genética , Factor sigma/genética , Tuberculosis Pulmonar/patologíaRESUMEN
Animal models of ricin toxicosis are necessary for testing the efficacy of therapeutic measures, as well studying the mechanisms by which ricin exerts its toxicity in intact animals. Because ricin can serve as a particularly well-characterized model of tissue damage, and the host response to that damage, studies of the mechanisms of ricin toxicity may have more general applicability. For example, our studies of the molecular mechanisms underlying the development of ricin-induced hypoglycemia may help elucidate the relationship of type II diabetes, insulin resistance, and inflammation. Studies in non-human primates are most relevant for testing and developing agents having clinical utility. But these animals are expensive and limited in quantity, and so rodents are used for most mechanistic studies.
Asunto(s)
Modelos Animales , Ricina/envenenamiento , Administración por Inhalación , Administración Oral , Animales , Inyecciones , Intestino Delgado/patología , Pulmón/patología , Macaca , Ratones , Ricina/administración & dosificación , Estómago/patologíaRESUMEN
Smallpox is considered a biological threat based upon the possibility of deliberate reintroduction into the population, creating an urgent need for effective antivirals. The antiviral drug cidofovir (Cr) has shown to be effective against poxviruses, although route-specific nephrotoxicity has hampered its development for emergency post-exposure prophylaxis (PEP). In this study, we use a micronized dry powder formulation of pharmaceutical-grade Cr (NanoFOVIRTM; Nf) to treat rabbits exposed to aerosolized rabbitpox virus (RPXV) to further evaluate the effectiveness of direct drug delivery to the lung. Naïve rabbits were infected with RPXV by aerosol; three subsets received aerosolized Nf at 0.5, 1.0 or 1.75mg/kg daily for 3days post-exposure, positive and negative control groups received intravenous (IV) Cr treatments and no treatment, respectively. Nf groups showed an antiviral-dose associated survival of 50% (0.5mg/kg), 80% (1.0mg/kg) and 100% (1.75mg/kg). All animals (100%) from the IV-Cr treatment group and none (0%) from the untreated controls survived. Nf (1.75) protected rabbits from RPX at approximately 10% of the equivalent IV-Cr dose. A dose-related effect was observed in clinical development of RPX disease in Nf groups. Significant reduction of RPX-induced pathological changes was observed in Nf (1.75) and IV-Cr groups. Results suggest that Nf may be a viable antiviral for emergency post-exposure prophylaxis and should be evaluated in other models of poxviral disease.
Asunto(s)
Antivirales/administración & dosificación , Citosina/análogos & derivados , Organofosfonatos/administración & dosificación , Profilaxis Posexposición , Virus Vaccinia , Vaccinia/prevención & control , Administración por Inhalación , Animales , Línea Celular , Cidofovir , Citosina/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Pulmón/patología , Pulmón/virología , Masculino , Conejos , Vaccinia/mortalidad , Vaccinia/virologíaRESUMEN
Tuberculosis (TB) is a major infectious disease problem: 1.7 million people annually die due to TB. Emergence of drug-resistant Mycobacterium tuberculosis and the lack of new antibiotics have exacerbated the situation. There is an urgent need to develop or repurpose drugs against TB. We evaluated inhaled gentamicin as direct respiratory system-targeted therapy in a murine model of TB. Aerosolized-gentamicin-treated mice showed significantly reduced lung M. tuberculosis loads and fewer granulomas relative to untreated controls. These results suggest that direct delivery of antibiotics to the respiratory system may provide therapeutic benefit to conventional treatment regimes for treatment of pulmonary TB.
Asunto(s)
Antituberculosos/administración & dosificación , Carga Bacteriana/efectos de los fármacos , Modelos Animales de Enfermedad , Gentamicinas/administración & dosificación , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis Pulmonar/tratamiento farmacológico , Administración por Inhalación , Animales , Antituberculosos/uso terapéutico , Femenino , Gentamicinas/uso terapéutico , Humanos , Pulmón/microbiología , Pulmón/patología , Ratones , Ratones Endogámicos C57BL , Resultado del Tratamiento , Tuberculosis Pulmonar/microbiología , Tuberculosis Pulmonar/patologíaRESUMEN
Conventional parenteral injection of vaccines is limited in its ability to induce locally-produced immune responses in the respiratory tract, and has logistical disadvantages in widespread vaccine administration. Recent studies suggest that intranasal delivery or vaccination in the respiratory tract with recombinant viral vectors can enhance immunogenicity and protection against respiratory diseases such as influenza and tuberculosis, and can offer more broad-based generalized protection by eliciting durable mucosal immune responses. Controlled aerosolization is a method to minimize vaccine particle size and ensure delivery to the lower respiratory tract. Here, we characterize the dynamics of aerosolization and show the effects of vaccine concentration on particle size, vector viability, and the actual delivered dose of an aerosolized adenoviral vector. In addition, we demonstrate that aerosol delivery of a recombinant adenoviral vaccine encoding H1N1 hemagglutinin is immunogenic and protects ferrets against homologous viral challenge. Overall, aerosol delivery offers comparable protection to intramuscular injection, and represents an attractive vaccine delivery method for broad-based immunization campaigns.
Asunto(s)
Adenoviridae/genética , Vectores Genéticos , Glicoproteínas Hemaglutininas del Virus de la Influenza/administración & dosificación , Subtipo H1N1 del Virus de la Influenza A/inmunología , Vacunas contra la Influenza/administración & dosificación , Infecciones por Orthomyxoviridae/prevención & control , Administración Intranasal , Aerosoles , Animales , Anticuerpos Antivirales/sangre , Hurones , Células HEK293 , Pruebas de Inhibición de Hemaglutinación , Glicoproteínas Hemaglutininas del Virus de la Influenza/genética , Glicoproteínas Hemaglutininas del Virus de la Influenza/inmunología , Humanos , Subtipo H1N1 del Virus de la Influenza A/genética , Vacunas contra la Influenza/genética , Vacunas contra la Influenza/inmunología , Masculino , Nebulizadores y Vaporizadores , Infecciones por Orthomyxoviridae/inmunología , Infecciones por Orthomyxoviridae/virología , Tamaño de la Partícula , Factores de Tiempo , Transfección , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunología , Carga ViralRESUMEN
The recently introduced Xpert MTB/RIF assay (Xpert) has point-of-care potential, but its capacity for biohazard containment remained to be studied. We compared the bioaerosols generated by the Xpert assay to acid-fast bacillus (AFB) microscope slide smear preparation. The Xpert assay sample treatment reagent (SR) was also studied for its sterilizing capacity, stability, and effect on assay sensitivity after prolonged treatment. During the preparation of AFB smears, sputum samples spiked with Mycobacterium bovis BCG at 5 × 10(8) CFU/ml produced 16 and 325 CFU/m(3) air measured with an Andersen impactor or BioSampler, respectively. In contrast, neither the sample preparation steps for the Xpert assay nor its automated processing produced any culturable bioaerosols. In testing of SR sterilizing capacity, clinical sputum samples from strongly smear-positive tuberculosis patients treated with SR at a 2:1 ratio eliminated Mycobacterium tuberculosis growth in all but 1/39 or 3/45 samples cultured on solid or liquid medium, respectively. These few unsterilized samples had a mean 13.1-day delay in the time to positive culture. SR treatment at a 3:1 ratio eliminated growth in all samples. SR retained a greater than 6-log-unit killing capacity despite storage at temperatures spanning 4 to 45°C for at least 3 months. The effect of prolonged SR sample treatment was also studied. Spiked sputum samples could be incubated in SR for up to 3 days without affecting Xpert sensitivity for M. tuberculosis detection and up to 8 h without affecting specificity for rifampin resistance detection. These results suggest that benchtop use of the Xpert MTB/RIF assay limits infection risk to the user.
Asunto(s)
Técnicas Bacteriológicas/métodos , Contención de Riesgos Biológicos/métodos , Mycobacterium bovis/aislamiento & purificación , Mycobacterium tuberculosis/aislamiento & purificación , Sistemas de Atención de Punto , Tuberculosis/prevención & control , Aerosoles , Microbiología del Aire , Antituberculosos/farmacología , Farmacorresistencia Bacteriana , Humanos , Rifampin/farmacología , Sensibilidad y Especificidad , Esputo/microbiología , Esterilización/métodosRESUMEN
In an effort to better understand the relationship between different fungal sampling methods in the indoor environment, four methods were used to quantify mold contamination in 13 homes with visible mold. Swab, fungal spore source strength tester (FSSST), and air samples (total of 52 samples) were analyzed using both the microscopic (total spore count) and culture-based (CFU count) enumeration techniques. Settled dust samples were analyzed for culturable fungi only, as the microscopic enumeration was restricted by the masking effect. The relationships between the data obtained with the different sampling methods were examined using correlation analysis. Significant relationships were observed between the data obtained from swab and FSSST samples both by the total counting (r = 0.822, p < 0.05) and by the CFU counting (r = 0.935, p < 0.01). No relationships were observed between air and FSSST samples or air and settled dust samples. Percentage culturability of spores for each sampling method was also calculated and found to vary greatly for all three methods (swab: 0.03% to 63%, FSSST: 0.1% to > 100%, air: 0.7% to 79%). These findings confirm that reliance on one sampling or enumeration method for characterization of an indoor mold source might not provide an accurate estimate of fungal contamination of a microenvironment. Furthermore, FSSST sampling appears to be an effective measurement of a mold source in the field, providing an upper bound estimate of potential mold spore release into the indoor air. Because of the small sample size of this study, however, further research is needed to better understand the observed relationships in this study.
Asunto(s)
Microbiología del Aire , Contaminación del Aire Interior/análisis , Monitoreo del Ambiente/métodos , Hongos/aislamiento & purificación , Contaminantes Atmosféricos/aislamiento & purificación , Recuento de Colonia Microbiana , Polvo/análisis , Hongos/clasificación , Vivienda , Ohio , Proyectos Piloto , Esporas Fúngicas/clasificación , Esporas Fúngicas/aislamiento & purificaciónRESUMEN
BACKGROUND: Respiratory protection devices are used to protect the wearers from inhaling particles suspended in the air. Filtering face piece respirators are usually tested utilizing nonbiologic particles, whereas their use often aims at reducing exposure to biologic aerosols, including infectious agents such as viruses and bacteria. METHODS: The performance of 2 types of N95 half-mask, filtering face piece respirators and 2 types of surgical masks were determined. The collection efficiency of these respiratory protection devices was investigated using MS2 virus (a nonharmful simulant of several pathogens). The virions were detected in the particle size range of 10 to 80 nm. RESULTS: The results indicate that the penetration of virions through the National Institute for Occupational Safety and Health (NIOSH)-certified N95 respirators can exceed an expected level of 5%. As anticipated, the tested surgical masks showed a much higher particle penetration because they are known to be less efficient than the N95 respirators. The 2 surgical masks, which originated from the same manufacturer, showed tremendously different penetration levels of the MS2 virions: 20.5% and 84.5%, respectively, at an inhalation flow rate of 85 L/min. CONCLUSION: The N95 filtering face piece respirators may not provide the expected protection level against small virions. Some surgical masks may let a significant fraction of airborne viruses penetrate through their filters, providing very low protection against aerosolized infectious agents in the size range of 10 to 80 nm. It should be noted that the surgical masks are primarily designed to protect the environment from the wearer, whereas the respirators are supposed to protect the wearer from the environment.
Asunto(s)
Microbiología del Aire , Contaminantes Ocupacionales del Aire/aislamiento & purificación , Exposición por Inhalación/prevención & control , Máscaras/virología , Dispositivos de Protección Respiratoria/virología , Virus/aislamiento & purificación , Humanos , Control de Infecciones/métodos , Levivirus/aislamiento & purificación , Máscaras/normas , Exposición Profesional/prevención & control , Dispositivos de Protección Respiratoria/normasRESUMEN
The airborne fungal spore concentration measured with air samplers during specific time intervals does not always adequately represent the maximum spore concentration levels, because of the sporadic nature of spore release. Hence, a reliable method is needed to directly assess the indoor fungal sources with respect to their spore aerosolization potential. In this study, the newly developed fungal spore source strength tester (FSSST), which aerosolizes spores from growth surfaces and samples the airborne fungi into a bioaerosol sampler, was evaluated in the laboratory. The FSSST's operational flow rates of 30 and 12.5 l/min were tested. The fungal spores released from moldy surfaces were measured with an optical particle counter. Simultaneously, the spores were collected by a bioaerosol sampler: either with a 37-mm filter cassette or with the BioSampler. Three material types, ceiling tile, gypsum board and plastic sheet coated with agar, were tested after they were inoculated with the fungus Aspergillus versicolor. In addition, gypsum board naturally contaminated with various fungi (obtained from a mold-problem home) was tested in the laboratory using the FSSST. In all three laboratory-inoculated materials, the release rate of A. versicolor was found to be higher when the FSSST operated at 30 l/min than at 12.5 l/min. Nevertheless, even at 12.5 l/min the number of spores aerosolized from the source during 10 min was found sufficient to reflect the highest level of release that may occur in indoor environments. At 12.5 l/min, the release rate of A. versicolor during the first 10-min period was (23.9 +/- 17.7)x10(4) cm(-2) for ceiling tile, (1.3 +/- 0.3)x10(4) cm(-2) for gypsum board and (0.13 +/- 0.08)x10(4) cm(-2) for agar surface (based on the samples collected with the BioSampler). The spore release rate was higher during the first 10 min than during the second 10 min of the FSSST application. It was observed that the particles aerosolized from the A. versicolor culture included spore aggregates and single spores, as well as mycelial fragments. Overall, 0.6 +/- 0.3% of spores detected on 1 cm2 of ceiling tile inoculated with A. versicolor were aerosolized during the 10-min source testing. The respective number was 9.2 +/- 1.0% for the laboratory-inoculated gypsum board, 0.002 +/- 0.001% for the laboratory-inoculated plastic covered with agar and 1.8 +/- 0.2% for naturally contaminated gypsum board. Our data suggest that the FSSST provides very favorable conditions for the spore aerosolization and thus can be used in the field to assess the maximum potential spore release from a fungal source.